Johnson & Johnson
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joaquin Duato
- Full Time Employees
- 141,700
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- One Johnson & Johnson Plaza New Brunswick NJ United States of America 08933
- IPO Date
- Jan 2, 1962
- CIK
- 0000200406
- Website
- jnj.com
- Similar Companies
- Business
- Johnson & Johnson is a global healthcare company engaged primarily in the research, development, manufacture, and sale of a broad range of pharmaceutical, medical device, and consumer health products. The company operates segments including Pharmaceuticals, Medical Devices, and Consumer Health, offering products such as prescription medicines for immunology, oncology, neuroscience, infectious diseases; orthopedic and surgical devices; and branded consumer healthcare products like Band-Aid and Listerine. Founded in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson serves customers worldwide across multiple markets. Recent major changes include Johnson & Johnson's 2025 acquisition of neurological drug maker Intra-Cellular Therapies for approximately $14.6 billion, expanding its neuroscience portfolio. In November 2025, J&J also announced the acquisition of Halda Therapeutics for $3.05 billion to bolster its oncology pipeline with innovations targeting metastatic castration-resistant prostate cancer. The company launched new cancer therapies Vykt, Tecvayli, and Talvey targeting multiple myeloma, generating $1.3 billion in sales in the first half of 2025. Furthermore, J&J is advancing drug candidates such as nipocalimab (Imaavy) for immune-mediated disorders and Caplyta for bipolar depression. The company also plans to divest its consumer health segment, signaling a strategic shift to focus more intensively on pharmaceuticals and medical devices. Johnson & Johnson continues to pursue regulatory approvals and expand indications for key drugs including SIMPONI, STELARA, TREMFYA, and Caplyta. It projects peak sales of several pipeline candidates at approximately $5 billion each. The firm remains heavily invested in research and development across immunology, oncology, neuroscience, and autoimmune diseases, leveraging innovative technologies including adenovirus vector and mRNA platforms. Johnson & Johnson reported a 6.8% sales increase to $24 billion in Q3 2025, reflecting operational growth driven by its pharmaceutical segment. This combination of advanced product portfolios, strategic acquisitions, and selective divestitures positions Johnson & Johnson as a leading global medical and pharmaceutical company focused on delivering innovative therapeutic solutions worldwide. The company's broad geographic operations span North America, Europe, Asia-Pacific, and emerging markets, catering to diverse healthcare needs across prescription drugs, medical devices, and consumer health products.
Three Dividend Strategies That Can Produce $7,500 a Month and Which One Comes Out Ahead
A Dividend Portfolio That Pays For Your Pets
Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner
Johnson & Johnson (JNJ) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
5 Words A Dividend Investor Never Wants To Hear, And Three Signs You Are About To Hear Them.
What Would It Take to Permanently Cover Long-Term Care Insurance Premiums?
The 20-Year Dividend Strategy Built For Investors Who Don’t Need Income Yet
How Large Does Your Portfolio Need to Be to Generate $12,000 a Month?
Jim Cramer: Buy the Dip on These 3 Stocks Now
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
The Big 3: UNH, KO, JNJ
FTSE 100 Live: AstraZeneca drags while Computacenter soars, US AI stocks gain
Fundstrat's Tom Lee: AI Is a Once in a Lifetime Story – Why Easing Inflation in H2 2026 Could Fuel the Next Rally
Why the Best Retirement Paycheck May Start Smaller Than You Expect
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?
The Retirement Portfolio That Pays You Without Demanding Constant Attention
The Case For Buying Smaller Dividends That Grow Faster
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
FuelCell Energy shares fall after company prices upsized $225M stock offering